News >

Carfilzomib Combos Deemed Safe in Multiple Myeloma

Angelica Welch
Published: Friday, Sep 14, 2018

Rafat Abonour, MD

Rafat Abonour, MD

Updated safety data of the ASPIRE and ENDEAVOR trials, which were presented at the 2018 SOHO Annual Meeting, showed that carfilzomib (Kyprolis)-based regimens demonstrate benefit across patient populations of multiple myeloma.

“Updated safety data from these 2 phase III trials are consistent with previous reports, and indicate that carfilzomib is well tolerated regardless of ASCT status,” concluded Abonour.

References

  1. Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36(8):728-734. doi: 10.1200/JCO.2017.76.5032.
  2. Stewart AK, Rajkumar V, Dimopoulos MA, et al; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015; 372(2):142-15 doi: 10.1056/NEJMoa1411321
  3. Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8.
  4. Dimopoulos MA, Moreau P, Palumbo A, et al; ENDEAVOR Investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x